Glucagon injection salesdeclined 25% to $20.6 million in Q2 2025, driven by increased competition and a market shift toward ...

Q2 2025 Management View CEO Ron Yekutiel reported "total revenue of $44.5 million for the second quarter of 2025, up 1% year-over-year and subscription revenue of $42.4 million, up 3% year-over-year," ...